Precision Medicine

Sensei Biotherapeutics begins a key trial for PIKTOR, a novel oral therapy aiming to outsmart cancer resistance in patients with advanced breast cancer.

A new FDA-cleared system offers hope against postpartum hemorrhage, the leading cause of maternal death, earning its maker a prestigious Edison Award.

Following a landmark FDA approval and strong earnings, Axsome must convince investors its momentum can translate into long-term profitability and leadership.

Promising data for its lead drug budoprutug has Climb Bio on a path to potentially redefine treatment for a range of debilitating autoimmune diseases.

A new biotech emerges with a promising, late-stage gene therapy for Sanfilippo syndrome, offering a potential lifeline for children with no other options.

This Vision Health Month, learn why your eyes need more than a simple check-up and how a surgeon's specialized medical expertise is key to preventing vision loss.

Valion Bio's new General Counsel, a rare blend of scientist and lawyer, is poised to navigate its radiation drug through the FDA's complex Animal Rule.

At the elite FiRe 2026 conference, Pattern Computer plans to unveil a 'hallucination-free' AI, promising a new era of scientific discovery and trust.

A novel medical food for IBS shows remarkable efficacy in new studies, exceeding FDA benchmarks for pain relief and solving the long-standing issue of taste.

A major investment in natural killer cell immunotherapy aims to revolutionize treatment for Canada's most fatal women's cancer after decades of stagnation.

The new Gibco CTS DynaXS bioreactor aims to unlock scalable production, making life-saving cell therapies more accessible and affordable for patients.

With its Juveena hydrogel pending FDA approval, Rejoni brings in a commercialization expert to tackle the underserved market for intrauterine adhesions.

A startup's partnership with industry giant Alcon promises to make vision assessment faster, more precise, and accessible to patients everywhere.

Pivotal trial results for a 3D-printed surgical guide show a dramatic drop in follow-up surgeries, heralding a new era of precision for patients.

A new partnership aims to combat a deadly infant disease, highlighting the critical role of human milk and corporate advocacy in saving the most vulnerable lives.

Noema Pharma's investigational drug cendifensine not only cut hot flashes by 92% but also aided weight loss and mood, promising a new non-hormonal era.

A national PSA campaign by Allergy & Asthma Network aims to combat severe health disparities and empower millions to manage their asthma effectively.

A new gene therapy has helped completely blind patients with Retinitis Pigmentosa regain light perception, offering hope to millions with inherited blindness.

Contineum Therapeutics reports encouraging early data for its non-opioid drug PIPE-791, offering a potential new weapon in the fight against chronic pain.

Eli Lilly begins a crucial Phase 2 study for a novel, non-addictive pain drug from Confo Therapeutics, a major step in the hunt for an opioid alternative.